[Drug releasing stents].
Drug eluting stents have become a mainstream in the treatment of coronary heart disease. Implementation of this technology into medical practice has resulted in a dramatic reduction in restenosis rates and late loss, which in turn is reflected in a significant reduction in MACE events due predominantly to a reduction in the need of a new re-intervention in the treated vessel. Historical comparisons between surgical results and the recently published studies with drug eluting stents shows that survival free of major events and the need of new revascularization are about the same in both groups of patients.
Ban Hayashi
Ernesto
E
Departamento de Hemodinámica, Instituto Nacional de Cardiología Ignacio Chávez INCICH, Juan Badiano No. 1, Col. Sección, XVI, Tlalpan, 14080 México D.F.
D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage; D002986:Clinical Trials as Topic; D003327:Coronary Disease / Q000188:drug therapy*; D016503:Drug Delivery Systems; D006801:Humans; D009131:Muscle, Smooth, Vascular / Q000187:drug effects; D017239:Paclitaxel / Q000008:administration & dosage; D020123:Sirolimus / Q000008:administration & dosage; D015607:Stents
D000903:Antibiotics, Antineoplastic; D000972:Antineoplastic Agents, Phytogenic; D017239:Paclitaxel; D020123:Sirolimus
Stents liberadores de fármacos.